Human Immunodeficiency Virus Prevention and the Potential of Drug Abuse Treatment

Clinical Infectious Diseases

Volumn 37, Issue 12 SUPPL. 5, 2003, Pages

  Metzger, David S ^a   Navaline, Helen ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT; COCAINE; DIAMORPHINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COCAINE DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; HEALTH BEHAVIOR; HEALTH CARE AVAILABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; MORPHINE ADDICTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PUBLIC HEALTH; SUBSTANCE ABUSE;

COCAINE-RELATED DISORDERS; DRUG AND NARCOTIC CONTROL; HEALTH EDUCATION; HIV; HIV INFECTIONS; HUMANS; PUBLIC HEALTH; RISK-TAKING; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 0348109302     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/377548     Document Type: Article

References (37)

1. Des Jarlais DC, Friedman SR, Hopkins W. Risk reduction for the acquired immunodeficiency syndrome among intravenous drug users. Ann Intern Med 1985; 103:755-9.
2. Normand J, Vlahov D, Moses LE. Preventing HIV transmission: the role of sterile needles and bleach. Washington, DC: National Academy Press, 1995.
3. Booth RE, Watters JK. How effective are risk-reduction interventions targeting injection drug users? AIDS 1994; 8:1515-24.
4. Cooper JR. Methadone treatment and acquired immunodeficiency syndrome. JAMA 1989; 262:1664-8.
5. Hubbard RL, Marsden ME, Rachal JV, Harwood HJ, Cavanaugh ER, Ginzburg HM. Drug abuse treatment: a national study of effectiveness. Chapel Hill, NC: University of North Carolina Press, 1989.
6. Gerstein DR, Harwood HJ Treating drug problems. Volume 1: a study of the effectiveness, and financing of public and private drug treatment systems. Washington, DC: National Academy Press, 1990.
7. Auerbach JD, Wypijewska C, Brodie HKH. AIDS and behavior: an integrated approach. Washington, DC: National Academy Press, 1994.
8. Strathdee SA, Galai N, Mahboobeh S, et al. Sex differences in risk factors for HIV seroconversion among injection drug users. Arch Intern Med 2001; 161:1281-8.
9. Haverkos HW. HIV/AIDS and drug abuse: epidemiology and prevention. J Addict Dis 1998; 17:91-103.
10. Orr MF, Glebatis D, Friedmann P, des Jarlais DC, Prevots DR. Incidence of HIV infection in a New York City methadone maintenance treatment program [letter]. JAMA 1996; 276:99.
11. Hubbard RL, Marsden ME, Cavanaugh E, Rachal JV, Ginzburg HM. Role of drug-abuse treatment in limiting the spread of AIDS. Rev Infect Dis 1988; 10:377-84.
12. McCusker J, Stoddard AM, Hindin RN, Garfield FB, Frost R. Changes in HIV risk behavior following alternative residential programs of drug abuse treatment and AIDS education. Ann Epidemiol 1996; 6:119-25.
13. Ball JC, Lange RL, Myers CP, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav 1988; 29:214-26.
14. Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer Verlag, 1991.
15. Booth RE, Crowley T, Zhang Y. Substance abuse treatment entry, retention, and effectiveness: out-of-treatment opiate injection drug users. Drug Alcohol Depend 1996; 42:11-20.
16. Hubbard RL, Craddock SG, Flynn PM, Anderson J, Etheridge RM. Overview of one year follow-up outcomes in the drug abuse treatment outcome study (DATOS). Psychol Addict Behav 1997; 11:261-8.
17. Caplehorn JRM, Ross MW. Methadone maintenance and the likelihood of risky needle sharing. Int J Addict 1995; 30:685-98.
18. Abdul-Quader AS, Friedman SR, Des Jarlais DC, Marmor MM, Maslansky R, Bartelme S. Methadone maintenance and behaviors by intravenous drug users that can transmit HIV. Contemp Drug Probl 1987; 14:425-33.
19. Avants SK, Margolin A, Sindelar JL, et al. Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost. Am J Psychiatry 1999; 156: 27-33.
20. Gossop M, Marsden J, Stewert D, Treacy S. Reduced injection risk and sex risk behaviours after drug misuse treatment: results from the National Treatment Outcome Research Study. AIDS Care 2002; 14:77-93.
21. Avins AL, Lindan CP, Woods WJ, et al. Changes in HIV-related behaviors among heterosexual alcoholics following addiction treatment. Drug Alcohol Depend 1997; 44:47-55.
22. Shoptaw S, Frosch D, Rawson RA, Ling W. Cocaine abuse counseling as HIV prevention. AIDS Educ Prev 1997; 9:511-20.
23. Gottheil E, Lundy A, Weinstein SP, Sterling RC. Does intensive outpatient cocaine treatment reduce AIDS risky behaviors? J Addict Dis 1998; 17:61-9.
24. Centers for Disease Control. Antibodies to a retrovirus etiologically associated with acquired immunodeficiency syndrome (AIDS) in populations with increased incidences of the syndrome. MMWR Morb Mortal Wkly Rep 1984; 33:377-9.
25. Novick DM, Kreek MJ, Des Jarlais DC, et al. Antibody to LAV, the putative agent of AIDS, in parenteral drug abusers and methadone-maintained patients: therapeutic, historical, and ethical aspects. NIDA Res Monogr 1986; 67:318-20.
26. Brown LS, Burkette W, Primm BJ. Drug treatment and HIV seropositivity [letter]. N Y State J Med 1988; 88:156.
27. Novick DM, Joseph H, Croxon TS, et al. Absence of antibody to human immunodeficiency virus in long term, socially rehabilitated methadone maintenance patients. Arch Intern Med 1990; 150:97-9.
28. Blix O, Gronbladh L. Impact of methadone maintenance treatment on the spread of HIV among IV heroin addicts in Sweden. In: Loimer N, Schmid R, Springer A, eds. Drug addiction and AIDS. New York: Springer-Verlag, 1991:200-5.
29. Moss AR, Vranizan K, Gorter R, Bachetti P, Watters J, Osmond D. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS 1994; 8:223-31.
30. Williams AB, McNelly EA, Williams AE, D'Aquila RT. Methadone maintenance treatment and HIV type 1 seroconversion among injection drug users. AIDS Care 1992; 4:35-41.
31. Serpelloni G, Carriere MP, Rezza G, Morganti S, Gomma M, Binkin N. Methadone treatment as a determinant of HIV risk reduction among injecting drug users: a nested case-controlled study. AIDS Care 1994; 6: 215-20.
32. Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among in-and out-of-treatment intravenous drug users: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 1993; 6:1049-56.
33. Friedman SR, Jose B, Deren S, Des Jarlais DC, Neaigus A. Risk factors for HIV seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. Am J Epidemiol 1995; 142:864-74.
34. Thiede H, Hagan H, Murrill CS. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health 2000; 77:331-44.
35. Metzger DS, Navaline H, Woody GE. Drug abuse treatment as HIV prevention. Public Health Rep 1998; 113(Suppl 1):97-106.
36. Sorensen J, Copeland A. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend 2000; 59:17-31.
37. Shuster CR. Intravenous drug use and HIV prevention. Public Health Rep 1988; 103:261-3.